Esperion Therapeutics (ESPR): Pivotal Bempedoic Acid Program Fully Underway - Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Esperion Therapeutics (ESPR) Initiates CVOT Trial for Bempedoic Acid
January 9, 2017 8:08 AM ESTEsperion Therapeutics, Inc. (NASDAQ: ESPR) announced the initiation of the global cardiovascular outcomes trial (CVOT) to assess the effects of bempedoic acid on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and considered statin intolerant.
The CVOT known as Cholesterol Lowering via... More
